Compromise on drug data transparency is necessary

07/8/2013 | Genetic Engineering & Biotechnology News

Compromise is needed in developing a system that makes clinical trial data as transparent as possible, together with appropriate protections for important data related to drugmakers' commercialization efforts as well as research and development, John Sterling writes. The Pharmaceutical Research and Manufacturers of America and drugmakers are against the European Medicines Agency's plan to make clinical trial information publicly available once a new treatment is approved due to concerns over the release of commercially protected information including intellectual property data.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care